FY2022 · ended Dec 31, 2022 · Revenue $3.11M, -74.7% YoY · Filed Mar 5, 2024
Aptevo Therapeutics Inc. (APVO) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $9.8 million in cash and investments and $4.2 million in total debt.
Revenue
$3.11M
-74.7% vs prior year
Net income
$-25.97M
-7.6% vs prior year
Operating cash flow (TTM)
$-25.34M
-2.8% vs year-ago TTM
Free cash flow
$-21.05M
+6.0% vs prior year
EPS
$-87.27
+99.7% vs prior year
Dividend per share
None
Shares outstanding
1.18M
-19.0% vs prior year
Net cash
$5.59M
as of Jun 30, 2026
Operating margin
-919.7%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APVO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671584
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $3.1M | $12.3M |
| Operating income | -$26.3M | -$24.6M | -$28.9M | -$28.6M | -$21.4M |
| Net income | -$26.0M | -$24.1M | -$17.4M | $8.0M | -$28.5M |
| Diluted EPS | -$87.27 | -$31,460.23 | -$2,316.83 | $1.57 | — |
| Operating cash flow | -$25.6M | -$23.8M | -$11.7M | -$21.0M | -$21.7M |
| Free cash flow | — | — | — | -$21.1M | -$22.4M |
| Total assets | $27.2M | $15.6M | $24.8M | $34.2M | $56.6M |
| Total liabilities | $9.8M | $10.8M | $12.6M | $16.2M | $55.4M |
| Stockholders' equity | $17.4M | $4.8M | $12.2M | $18.0M | $1.2M |
| Cash and investments | $21.6M | $8.7M | $16.9M | $22.6M | $45.0M |
| Total debt | $4.6M | $5.4M | $6.1M | $10.5M | $17.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Other events
|
Nov 2, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Other events
|
Sep 24, 2026 | Sep 24, 2026 |
All 740 Aptevo Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.